指南与共识

ASCO-FCR最小年龄工作组:临床试验入组年龄现代化建议

Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group.
指南 / 共识 · J Clin Oncol · 2017-10-02

ASCO与癌症研究之友于2016年召开多利益相关方研讨会,评估将18岁以下儿童纳入首次人体试验及成人肿瘤临床试验的障碍。工作组认为许多历史担忧在当前儿科肿瘤与药物开发环境下不再适用,并给出具体建议:在评估剂量、安全性和药代动力学的早期试验及覆盖成人与儿童特定疾病的后期试验中,可自动纳入儿科患者。结论认为在合理设计的成人肿瘤临床试验中纳入儿童可行,且不损害安全性或开发策略。

要点

  • 历史担忧不再适用当前儿科肿瘤与药物开发环境。
  • 评估剂量、安全性和药代动力学的早期试验可自动纳入儿科患者。
  • 覆盖成人与儿童特定疾病的后期疗效试验可自动纳入儿科患者。

核心结论

  • 在合理设计的成人肿瘤临床试验中纳入儿童可行,可增加其获取新药机会而不损害安全性或开发策略。

研究设计与样本

  • ASCO与Friends of Cancer Research于2016年5月召开多利益相关方研讨会,汇集学术界、政府和产业界专家。
  • 工作组评估了历史背景、已发表文献、监管考虑及降低入组年龄的多种风险与获益。

主要发现

  • 许多关于早期纳入儿童的历史担忧在当前儿科肿瘤与药物开发环境中不适用。
  • 工作组提供了在早期研究中纳入儿童的具体建议。

关键数值与推荐

  • 评估多种肿瘤类型剂量、安全性和药代动力学的早期试验可自动纳入儿科患者。
  • 评估覆盖成人与儿童特定疾病疗效的后期试验可自动纳入儿科患者。

临床怎么用

  • 在评估剂量、安全性和药代动力学的早期试验中可自动纳入儿科患者。
  • 在覆盖成人与儿童特定疾病的后期疗效试验中可自动纳入儿科患者。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Children have historically been excluded from first-in-human studies of promising new cancer drugs and later phase adult clinical trials. Delays in evaluation may result in off-label use without dosing information as the only access to new drugs. A multistakeholder workshop was convened in May 2016 by ASCO and Friends of Cancer Research to identify opportunities for when it would be scientifically appropriate to expand trial eligibility to include children younger than age 18 years in first-in-human and other adult cancer clinical trials. Methods This group convened experts from academia, government, and industry to review barriers to enrolling children and adolescents in oncology clinical trials. We evaluated the historical context, published literature, regulatory considerations, and myriad risks and benefits associated with lowering the age of enrollment on oncology clinical trials. Results We conclude that many of the historical concerns about including children early in oncology clinical trials do not apply in the current scientific and clinical environment of pediatric oncology and drug development; we provide specific recommendations for how the inclusion of children in early-phase investigational cancer drug trials might be accomplished. Automatic inclusion of pediatric patients is appropriate in early-phase trials that assess dose, safety, and pharmacokinetics in a variety of tumor types and later phase trials that assess efficacy in a specific disease that spans adult and pediatric populations. Conclusion Including children in appropriately designed adult clinical oncology trials is feasible and can be done in a way that enhances their access to these agents without compromising safety or development strategies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gore L, Ivy SP, Balis FM, et al. Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group. J Clin Oncol. 2017. PMID: 28968169. doi:10.1200/JCO.2017.74.4144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。